Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' - PubMed (original) (raw)

Review

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'

George L Drusano. Nat Rev Microbiol. 2004 Apr.

No abstract available

PubMed Disclaimer

Similar articles

• Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection.
  Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Bradley JS, et al. Pediatr Infect Dis J. 2010 Nov;29(11):1043-6. doi: 10.1097/INF.0b013e3181f42a53. Pediatr Infect Dis J. 2010. PMID: 20975453 Review. No abstract available.
• Pharmacokinetics/Pharmacodynamics for critical care clinicians.
  Quintiliani R Sr, Quintiliani R Jr. Quintiliani R Sr, et al. Crit Care Clin. 2008 Apr;24(2):335-48, xi. doi: 10.1016/j.ccc.2007.12.008. Crit Care Clin. 2008. PMID: 18361949 Review.
• Tools to define the relevance of PK/PD parameters to the efficacy, toxicity and emergence of resistance of antimicrobials.
  Hickey E. Hickey E. Curr Opin Drug Discov Devel. 2007 Jan;10(1):49-52. Curr Opin Drug Discov Devel. 2007. PMID: 17265741 Review.
• Pharmacodynamics of antimicrobial drugs.
  Levison ME. Levison ME. Infect Dis Clin North Am. 2004 Sep;18(3):451-65, vii. doi: 10.1016/j.idc.2004.04.012. Infect Dis Clin North Am. 2004. PMID: 15308272 Review.
• [Recurrent uncomplicated urinary tract infection in young woman].
  Hoyme UB. Hoyme UB. MMW Fortschr Med. 2008 Jun 26;150(26-27):54-5. MMW Fortschr Med. 2008. PMID: 18681234 German. No abstract available.

Cited by

• Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure-Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli.
  Seeger J, Guenther S, Schaufler K, Heiden SE, Michelet R, Kloft C. Seeger J, et al. Antibiotics (Basel). 2021 May 21;10(6):615. doi: 10.3390/antibiotics10060615. Antibiotics (Basel). 2021. PMID: 34063980 Free PMC article.
• Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.
  Trivedi A, Lee RE, Meibohm B. Trivedi A, et al. Expert Rev Clin Pharmacol. 2013 Mar;6(2):159-70. doi: 10.1586/ecp.13.6. Expert Rev Clin Pharmacol. 2013. PMID: 23473593 Free PMC article. Review.
• In vivo antimicrobial activity of marbofloxacin against Pasteurella multocida in a tissue cage model in calves.
  Cao C, Qu Y, Sun M, Qiu Z, Huang X, Huai B, Lu Y, Zeng Z. Cao C, et al. Front Microbiol. 2015 Jul 24;6:759. doi: 10.3389/fmicb.2015.00759. eCollection 2015. Front Microbiol. 2015. PMID: 26257726 Free PMC article.
• Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing.
  Liu X, Zheng H, Zhang W, Shen Z, Zhao M, Chen Y, Sun L, Shi J, Zhang J. Liu X, et al. Front Microbiol. 2016 Aug 19;7:1268. doi: 10.3389/fmicb.2016.01268. eCollection 2016. Front Microbiol. 2016. PMID: 27594850 Free PMC article.
• Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy.
  Lewis SJ, Mueller BA. Lewis SJ, et al. BMC Nephrol. 2024 Feb 27;25(1):73. doi: 10.1186/s12882-024-03469-2. BMC Nephrol. 2024. PMID: 38413858 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information